Altemia (docosahexaenoic acid) / Micelle BioPharma - LARVOL DELTA

Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. (PubMed, Sci Rep) - "To compare the efficacy and safety of the proposed aflibercept biosimilar SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration, this randomized, double-masked, parallel-group, multicenter study was conducted in 14 countries from 13 August 2020 to 8 September 2022. In conclusion, SCD411 has equivalent efficacy compared with reference aflibercept in patients with neovascular age-related macular degeneration and has a comparable safety profile. The results support the potential use of SCD411 for the treatment of neovascular age-related macular degeneration."

Clinical • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Pharmacological intervention for pain management in paediatric sickle cell anaemia patient: A network meta-analysis (BSH 2024) - "The analysis indicated that hydroxyurea was the most effective pharmacological treatment in decreasing acute chest syndrome (ACS) incidences (Odds ratio [OR] 0.39 95% CI [0.17; 0.90], p=0.02) and hospitalisation (OR 0.32 95% CI [0.16; 0.64], p=0.001), SC411 was superior in preventing vasoocclusive crisis (VOC) incidence (OR 0.47 95% CI [0.23; 0.97], p=0.04), ketorolac (mean difference [MD] −4.18 95% CI [−5.91; −2.44], p<0.0001) and arginine (MD −2.06 95% CI [−2.48; −1.64], p<0.0001) was effective in decreasing pain intensity in SCA paediatric patients, dexamethasone was efficient in decreasing transfusions (OR 0.19 95% CI [0.05; 0.77], p=0.02) and severe adverse events (SAEs) (OR 0.19 95% CI [0.05; 0.77], p=0.02) in paediatric SCA patients. This study shows the significant efficacy of various pharmacological treatments in reducing the symptoms of SCA, such as the number of hospitalizations, ACS, VOC, SAEs and pain intensity over the placebo group. However, the..."

Retrospective data • Anemia • Genetic Disorders • Hematological Disorders • Pain • Pediatrics • Sickle Cell Disease

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - P3 | N=576 | Completed | Sponsor: Sam Chun Dang Pharm. Co. Ltd. | Active, not recruiting ➔ Completed

Trial completion • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Characterization of Phytochemicals in Ulva intestinalis L. and Their Action Against SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain. (PubMed, Front Chem) - "The results indicated that mainly phenols, polyenes, phytosteroids, and aliphatic compounds from the extract, such as 2,4-di-tert-butylphenol (2,4-DtBP), doconexent, 4,8,13-duvatriene-1,3-diol (DTD), retinoyl-β-glucuronide 6',3'-lactone (RBGUL), and retinal, showed better binding affinity to the target. Pharmacokinetic validation narrowed the list to 2,4-DtBP, retinal and RBGUL as the possible antiviral candidates that could inhibit the viral spike protein effectively."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Docosahexaenoic acid demonstrates anti-tumorigenic effects in endometrial cancer (UNC Lineberger) - "DHA robustly inhibited EC proliferation and tumor growth in vitro and in vivo Omega-3 PUFA supplementation may be a promising dietary strategy for endometrial cancer prevention and treatment."

Preclinical

Grapefruit-Derived Micro and Nanovesicles Show Distinct Metabolome Profiles and Anticancer Activities in the A375 Human Melanoma Cell Line. (PubMed, Cells) - "Grapefruit-derived NVs are in particular rich in alpha-hydroxy acids and leucine/isoleucine, myo-inositol and doconexent, while quininic acid was detected in MVs. Our findings reveal the metabolite signatures of grapefruit-derived vesicles and substantiate their potential use in new anticancer strategies."

Journal • Preclinical • Breast Cancer • Melanoma • Metabolic Disorders • Oncology • Solid Tumor • CTSS

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - P3; N=560; Recruiting; Sponsor: Sam Chun Dang Pharm. Co. Ltd.; Not yet recruiting ➔ Recruiting; Trial completion date: Jan 2022 ➔ Apr 2022

Clinical • Enrollment open • Trial completion date • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - P3; N=560; Not yet recruiting; Sponsor: Sam Chun Dang Pharm. Co. Ltd.

Clinical • New P3 trial • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

SC411 treatment can enhance survival in a mouse model of sickle cell disease. (PubMed, Prostaglandins Leukot Essent Fatty Acids) - "In summary, this study suggests that treatment with SC411 improves cellular and functional outcomes in SCD mice. This finding may provide novel therapeutic opportunities in the treatment against ischemic injury elicited by SCD."

Journal • Complement-mediated Rare Disorders • Gene Therapies • Genetic Disorders • Hematological Disorders • Immunology • Reperfusion Injury • Sickle Cell Disease